MBX Biosciences, Inc. Common Stock (MBX)

NASDAQ • Healthcare

$48.5

-$1.96 (-3.9%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$50.15

Previous Close$48.5

Day Range$47.5 - $50.15

Avg. Volume (3M)588.5K

Market Cap$2.3B

52 Week Range

$16.91$72.64

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$104.2M

EPS (TTM)

-$2.4

ROA (TTM)

-23.93%

Current Ratio

18.08

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+24.7%Q3 2025-$0.58

+13.7%Q4 2025-$0.63

+23.4%Q1 2026-$0.49

+17.7%Q2 2026-$0.51

-23.3%Q3 2026-$0.78

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -23.3%

MBX Biosciences missed on EPS in the second fiscal quarter of 2026, with preliminary results reported Aug. 6 showing EPS of -$0.78 versus the -$0.63 estimate, about -23%, and down 34.5% from -$0.58 a year earlier. Net income came in at roughly negative $37.1 million, down 91.1% from negative $19.4 million a year ago, while operating income was about negative $40.9 million and operating cash flow was negative about $42.8 million. Consensus for the next period calls for EPS of -$0.78.

Next report — what to expect

MBX Biosciences, Inc. Common Stock (MBX) is set to report on November 5, 2026. Consensus calls for EPS of -$0.83. It has beaten EPS in 6 of 8 most recent quarters, so traders will be watching whether results again come in ahead of expectations alongside any commentary that frames the next quarter.

View full earnings history

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a clinical-stage biotechnology company listed on the NASDAQ as MBX that develops precise peptide-based therapies for endocrine and metabolic conditions. Its work centers on peptide drug candidates aimed at hormone and metabolic disorders rather than marketed products, placing the company in the biopharmaceutical development phase.

Name

MBX Biosciences, Inc. Common Stock

CEO

Steve Hoerter

Website

mbxbio.com

Industry

Healthcare

Year Founded

2018

Employees

Today's Snapshot

AI-generated

The day ended with MBX 3.9% lower at 48.50, in line with a weaker sector. MBX is due to report earnings on 5 November.

Trading Volume

Below 10d avg (711.3K)

574.7K

vs S&P 500 Today

Strong Underperformance

-3.36%

Updated: October 23, 2026 at 20:20 UTC

Technical Indicators

1 Buy2 Neutral5 Sell

MBX presents a clear sell profile as short- and medium-term momentum have turned negative and the price has slipped below multiple moving averages while remaining only marginally above the 200-day averages. MACD and CCI readings are decisively bearish and momentum is down, reflecting downside pressure, and the pivot level sits well above the current price as nearby resistance. ATR is elevated, signaling larger intraday moves on weakness, and on-balance volume favors the downside. ADX is moderate, so the trend has some conviction but is not extreme. Technical takeaway: sell while short- and medium-term momentum and momentum-based indicators remain negative.

All signals

EMA (5 indicators)$45.71 - $56.27
Sell
RSI (14)35.56
Neutral
Stochastic %K (14, 3, 3)26.62
Neutral
MACD Level (12, 26)-2.45
Sell

Peers & Related Assets

RYTMRhythm Pharmaceuticals, Inc.

$89.27-1.8%

VKTXViking Therapeutics, Inc.

$24.4-5.5%

XERSXeris Biopharma Holdings, Inc.

$10.2-6.1%

ALTAltimmune, Inc.

$2.12-2.3%

ASNDAscendis Pharma A/S

KLRAKailera Therapeutics, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.